Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture

Cancer Investigation

Volumn 24, Issue 1, 2006, Pages 28-34

  Eisenthal, Avi ^a,b   Barbarsteyn, Elena ^a   Gitstein, Gilad ^a   Lifschitz Mercer, Beatriz ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cytotoxicity; Inhibition; LAK cells; Melanoma; TGF beta

Indexed keywords

BIOLOGICAL FACTOR; INTERLEUKIN 2; SODIUM CHROMATE CR 51; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ASSAY; CELL ACTIVITY; CELL ADHESION; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; MIXED CELL CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SUPERNATANT; TUMOR CELL;

CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MELANOMA;

EID: 32644459129     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500449561     Document Type: Article

References (32)

1. Hoyer, M.; Meineke, T.; Lewis, W.; Zwilling, B.; Reinehart, J. Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction. Cancer. Res. 1986, 46, 2834-2838.
2. Lotze, M.T.; Grimm, E.A.; Mazumder, A.; Strausser, J.L.; Rosenberg, S.A. In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T-cell growth factor (TCGF). Cancer. Res. 1981, 41, 4420-4425.
3. Lafreniere, R.; Rosenberg, S.A.; Adoptive immunotherapy of murine hepatic metastases with lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (r-IL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and adenocarcinoma. J. Immunol. 1985, 135, 4273-4280.
4. Mule, J.J.; Shu, S.; Schwarz, S.L.; Rosenberg, S.A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984, 225, 1487-1489.
5. Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Chang, A.E.; Avis, F.P.; Leitman, S.; Linehan, W.M.; Robertson, C.N.; Lee, R.E.; Rubin, J.T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 1987, 316, 889-897.
6. Margolin, K.A.; Rayner, A.A.; Hawkins, M.J.; Atkins, M.B.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.R.; Doroshow, J.H.; Jaffe, H.S.; Roper, M.; et al. Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol. 1989, 7, 486-498.
7. Pockaj, B.; Sherry, R.M.; Wei, J.P.; Yannelli, J.R.; Carter, C.S.; Leitman, S.F.; Carasquillo, J.A.; Steinberg, S.M.; Rosenberg, S.A.; Yang, J.C. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994, 73, 1731-1737.
8. Lala, P.K.; Parhar, R.S. Cure of B16F10 melanoma lung metastases in mice by chronic indomethacin therapy combined with repeated rounds of interleukin-2: characteristics of killer cells generated in situ. Cancer Res. 1988, 48, 1072-1079.
9. Skelsey, M.E.; Mayhew, E.; Niederkorn, J.Y. CD25+, interleukin-10- producing CD4+ T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology 2003, 110, 18-29.
10. Eisenthal, A.; Chaitchik, S.; Skornick, Y. Enhancement of interleukin-2 induced lymphokine-activated killer cells and antibody-dependent cellular cytotoxicity activities by indomethacin and superoxide dismutase. Immunology. Life Sci. Adv. 1991, 10, 77-86.
11. Jiang, H.; Stewart, C.A.; Fast, D.J.; Leu, R.W. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target. J. Immunol. 1992, 149, 2137-2146.
12. Billiau, A.D.; Sefrioui, H.; Overbergh, L.; Rutgeerts, O.; Goebeles, J.; Mathieu, C.; Waer, M. Transforming growth factor beta inhibits lymphokine-activated killer cytotoxicity of bone marrow cells: implication for the graft vs. leukemia effect in irradiation allogeneic bone marrow chimeras. Transplantation 2001, 71, 292-299.
13. Medrano, E.E. Repression of TGF-β signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival and metastases. Oncogene. 2003, 22, 3123-3129.
14. Strasnick, B.; Lagos, N.; Lichtenstein, A.; Mickel, R.A. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck. Otolaryngol. Head Neck. Surg. 1990, 103, 537-549.
15. Ivanovic, V.; Todorovic-Rakovic, N.; Demajo, M.; Neskovic-Konstantinovic, Z.; Subota, V.; Ivanisevic-Milovanovic, O.; Nikolic-Vukosavljevic, D. Elevated plasma levels of transforming growth factor-beta 1 in patients with advanced breast cancer: association with disease progression. Eur. J. Cancer 2003, 39, 454-461.
16. Kong, F.M.; Anscher, M.S.; Murase, T.; Abbott, B.D.; Iglehart, J.D.; Jirtle, R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. 1995, 222, 155-162.
17. Mantovani, A.; Bottazzi, B.; Colotta, F.; Sozzani, S.; Ruco, L. The origin and function of tumor-associated macrophages. Immunol. Today 1992, 13, 265-270.
18. Saio, M.; Radoja, S.; Marino, M.; Frey, A.B. Tumor infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediate both the cell-association form of TNF and nitric oxide. J. Immunol. 2001, 167, 5583-5593.
19. Joseph, I.B.J.K.; Isaacs, J.T. Macrophages role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer. Inst. 1998, 90, 1648-1653.
20. Kono, K.; Salazar-Onfray, F.; Petersson, M.; Hansson, J.; Masucci, G.; Wasserman, K.; Nakazawa, T.; Anderson, P.; Kiessling, R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 1996, 26, 1308-1313.
21. Hellstrand, K.; Asea, A.; Dahlgren, C.; Hermodsson, S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites, J. Immunol. 1994, 153, 4940-4947.
22. Lokhart, D.C.; Chan, A.K.; Mak, S.; Joo, H.G.; Daust, H.A.; Carritte, A.; Douville, C.C.; Goedegebuure, P.S.; Eberline, T.J. Loss of T-cell receptor-CD3zeta and T-cell function in tumor infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001, 129, 749-756.
23. White, E.S.; Strom, S.R.B.; Wys, N.L.; Arenberg, D.A. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. Immunology 2001, 166, 7549-7555.
24. Horn, D.; Van Der Bosch, J.; Puller, S.; Schlaak, M. Suppression of tumor cell susceptibility to monocyte-induced cell death by growth-inhibitory signals generated during monocyte/tumor cell interaction. J. Cell. Biochem. 1991, 45, 213-223.
25. Eisenthal, A.; Skornick, Y.; Ron, I.; Zakuth, V.; Chaitchik, S. Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy. Cancer. Immunol. Immunother. 1993, 37, 367-372.
26. Harthun, N.L.; Weaver, A.M.; Brinckerhoff, L.H,; Deacon, D.H.; Gonias, S.L.; Slingluff, C.L. Jr. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. J. Immunother. 1998, 21, 85-94.
27. Roth, M.D.; Golub, S.H. Human pulmonary macrophages utilize prostaglandins and transforming growth factor beta 1 to suppress lymphocyte activation. J. Leukoc. Biol. 1993, 53, 366-371.
28. Sano, C.; Shimizu, T.; Sato, K.; Kawaucji, H.; Tomioka, H. Effects of secretory protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta) by lipopolysaccharide-stimulated macrophages. Clin. Exp. Immunol. 2000, 121, 77-85.
29. Bergmann, L.; Schui, D.K.; Brieger, J.; Weidmann, E.; Mitrou, P.S.; Hoelzer, D. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. Exp. Hematol. 1995, 23, 1574-1580.
30. Guillou, P.J.; Sedman, P.C.; Ramsden, C.W. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer. Immunol. Immunother. 1989, 28, 43-53.
31. Guillou, P.J.; Ramsden, C.W.; Somers, S.S.; Sedman, P.C. Suppression of the generation of lymphokine-activated killer cells by serum-free supernatants of the in vitro maintained tumor cell lines. Br. J. Cancer 1989, 59, 515-521.
32. Henkart, P.A.; Yue, C.C.; Yang, J.; Rosenberg, S.A. Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells. J. Immunol. 1986, 137, 2611-2617.